MedTrace Logo

Gene Expression Profiles and Metformin Efficacy in Type 2 Diabetes

NCT01334684 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-04-13

No results posted yet for this study

Summary

Our general aim is to investigate whether messenger RNA (mRNA) and/or microRNA (miRNA) expression profiles in white blood cells, predict metformin monotherapy efficacy in patients with type 2 diabetes.

Conditions

Interventions

DRUG

Metformin

Metformin, pills, 850 mg three times a day for three months

Sponsors & Collaborators

  • University Hospital, Catania

    collaborator OTHER

  • Casa Sollievo della Sofferenza IRCCS

    lead OTHER

Principal Investigators

  • Salvatore De Cosmo, MD · Casa Sollievo della Sofferenza IRCCS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-04-30
Completion
2013-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334684 on ClinicalTrials.gov